1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 PLEXXIKON INC., Case No. 17-cv-04405-HSG
8 Plaintiff, ORDER DENYING DEFENDANT’S MOTION FOR LEAVE TO FILE 9 v. SECOND SUMMARY JUDGMENT MOTION 10 NOVARTIS PHARMACEUTICALS CORPORATION, Re: Dkt. No. 345 11 Defendant. 12
13 Defendant Novartis Pharmaceuticals Corporation (“Novartis”) seeks leave to file a second 14 summary judgment motion. Dkt No. 345 (“Mot.”). The deadline for dispositive motions has 15 passed and the case is scheduled for trial in June 2020. Nevertheless, Novartis argues that the 16 Federal Circuit’s recent decision in Idenix Pharmaceuticals LLC v. Gilead Sciences Inc., 941 F.3d 17 1149 (Fed. Cir. 2019), constitutes intervening law and provides good cause to deviate from the 18 scheduling and standing orders. The Court finds this matter appropriate for disposition without 19 oral argument and the matter is deemed submitted. See Civil L.R. 7-1(b).” For the reasons 20 detailed below, the Court DENIES the motion. 21 The Court’s standing order limits each party to filing one motion for summary judgment 22 and requires a party seeking to exceed that limit to show “good cause.” Standing Order for Civil 23 Cases Before District Judge Haywood S. Gilliam, Jr. (“Standing Order”) ¶ 17. The Standing 24 Order reflects policy disfavoring piecemeal litigation in federal courts. See Peasley v. Spearman, 25 No. 15-cv-01769-LHK, 2017 WL 5451709, at *3 (N.D. Cal. Nov. 14, 2017); see also Allstate Fin. 26 Corp. v. Zimmerman, 296 F.2d 797, 799 (5th Cir. 1961) (disapproving of successive motions 27 because “parties ought to be held to the requirement that they present their strongest case for 1 “district courts have discretion to permit successive motions for summary judgment,” and that 2 doing so may “foster[] the ‘just, speedy, and inexpensive’ resolution of suits.” Hoffman v. 3 Tonnemacher, 593 F.3d 908, 911 (9th Cir. 2010) (quoting Fed. R. Civ. P. 1). Because of the 4 potential for abuse, courts retain discretion to “weed out frivolous or simply repetitive motions.” 5 Id. (quotation omitted). Additionally, district courts have broad authority to manage their dockets 6 and deny untimely motions absent good cause. Dietz v. Bouldin, 136 S.Ct. 1885, 1891–93 (2016); 7 Zivkovic v. Southern California Edison Co., 302 F.3d 1080, 1086 (9th Cir. 2002). 8 Novartis urges that a second summary judgment motion is warranted here, in light of 9 Idenix, because “all of the asserted claims are invalid for lack of enablement . . . .” See Mot. at 1– 10 2. Having considered Novartis’s arguments, the Court finds that Novartis fails to show good 11 cause to file a second motion for summary judgment. First, Idenix does not represent a change in 12 law that justifies Novartis’s delay in bringing the motion. In Idenix, the Federal Circuit considered 13 whether claims reciting compounds having a certain chemical formula, in addition to functional 14 limitations requiring an “effective” dose “for the treatment of a hepatitis C virus infection,” were 15 enabled. 941 F.3d at 1153–56. The court found that the claims were not enabled because 16 excessive experimentation was required to determine which compounds of the recited formula 17 were “effective against HCV.” Id. at 1162. In so doing, the court expressly noted that “[o]ur 18 decision in Wyeth and Cordis Corp. v. Abbott Laboratories compels this conclusion.” Id. In 19 Wyeth, the court had similarly found that claims that recited both functional and structural 20 limitations were not enabled because a person of ordinary skill in the art would have to test “tens 21 of thousands of compounds” to determine if they met the functional limitations. 720 F.3d 1380, 22 1384–85 (Fed. Cir. 2013). 23 Novartis provides no explanation as to why it could not have brought its desired motion 24 previously under Wyeth. A cursory examination of both cases shows that Idenix applies the rule 25 established in Wyeth and addresses a “striking[ly]” similar set of facts. 941 F.3d at 1162. 26 Accordingly, Novartis fails to show that it acted diligently, and therefore that it has good cause to 27 file the second motion for summary judgment after the dispositive motion deadline. See Johnson 1 cause” standard for modifying a schedule “primarily considers the diligence of the party seeking 2 the amendment”). 3 Second, the decision in Idenix does not apply to the current facts. The court in Idenix 4 addressed the question of whether “practicing the full scope of the claims would have required 5 excessive experimentation.” 941 F.3d at 1156, 1163. The claims there were limited to the “set of 6 compounds that are effective for treatment of HCV.” Id. at 1155 (quoting the claim construction 7 order). Thus, because the specification did not describe which compounds were effective for 8 treatment of HCV, it failed to enable “the full scope of the claims.” Id. at 1163. Here, in its 9 opening brief, Novartis argues that the asserted claims are not enabled because the specification 10 does not specify the compounds that are effective at inhibiting kinase. But kinase inhibition is not 11 a limitation of the asserted claims. See Dkt. No. 345-2 (“Proposed MSJ”) at 2:22–5:24 (quoting 12 asserted claims). At most, only claims 11 and 12 of the ’640 Patent even recite functional 13 limitations—but those limitations describe “treating a subject suffering from melanoma, thyroid 14 cancer or colorectal cancer,” not inhibiting kinase. See id. Thus, the specifications need not 15 enable compounds that inhibit kinase to allow a person of ordinary skill in the art to practice “the 16 full scope of the claims,” and Novartis’s motion will not resolve the dispute.1 See Idenix, 941 F.3d 17 at 1156. 18 Novartis changes tack in its reply, suggesting that its motion is also proper under the utility 19 standard of 35 U.S.C § 101, as utility is incorporated into the enablement analysis. See Dkt. No. 20 353 at 2, 5–6. Although Novartis is correct that utility has been incorporated into the enablement 21 standard, the two are not coextensive and require different types of analysis. See In re ’318 Patent 22 Infringement Litig., 583 F.3d 1317, 1323 (Fed. Cir. 2009) (noting enablement is “closely related” 23 to utility); Rasmusson v. SmithKline Beecham Corp., 413 F.3d 1318, 1323 (Fed. Cir. 2005) 24 1 Novartis argues in its reply that “every claim in the asserted patents is directed to compounds 25 that are useful as kinase inhibitors.” Dkt. No. 353 (“Reply”) at 6:10–11. However, “[i]t is a bedrock principle of patent law that ‘the claims of a patent define the invention to which the 26 patentee is entitled the right to exclude.’” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005) (en banc) (citation omitted). Since kinase inhibition is not required by the claims, it is not 27 required to practice the claimed invention. See CFMT, Inc. v. Yieldup Int’l Corp., 349 F.3d 1333, 1 (explaining how lack of usefulness leads to a rejection under both enablement and utility).
Free access — add to your briefcase to read the full text and ask questions with AI
1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 PLEXXIKON INC., Case No. 17-cv-04405-HSG
8 Plaintiff, ORDER DENYING DEFENDANT’S MOTION FOR LEAVE TO FILE 9 v. SECOND SUMMARY JUDGMENT MOTION 10 NOVARTIS PHARMACEUTICALS CORPORATION, Re: Dkt. No. 345 11 Defendant. 12
13 Defendant Novartis Pharmaceuticals Corporation (“Novartis”) seeks leave to file a second 14 summary judgment motion. Dkt No. 345 (“Mot.”). The deadline for dispositive motions has 15 passed and the case is scheduled for trial in June 2020. Nevertheless, Novartis argues that the 16 Federal Circuit’s recent decision in Idenix Pharmaceuticals LLC v. Gilead Sciences Inc., 941 F.3d 17 1149 (Fed. Cir. 2019), constitutes intervening law and provides good cause to deviate from the 18 scheduling and standing orders. The Court finds this matter appropriate for disposition without 19 oral argument and the matter is deemed submitted. See Civil L.R. 7-1(b).” For the reasons 20 detailed below, the Court DENIES the motion. 21 The Court’s standing order limits each party to filing one motion for summary judgment 22 and requires a party seeking to exceed that limit to show “good cause.” Standing Order for Civil 23 Cases Before District Judge Haywood S. Gilliam, Jr. (“Standing Order”) ¶ 17. The Standing 24 Order reflects policy disfavoring piecemeal litigation in federal courts. See Peasley v. Spearman, 25 No. 15-cv-01769-LHK, 2017 WL 5451709, at *3 (N.D. Cal. Nov. 14, 2017); see also Allstate Fin. 26 Corp. v. Zimmerman, 296 F.2d 797, 799 (5th Cir. 1961) (disapproving of successive motions 27 because “parties ought to be held to the requirement that they present their strongest case for 1 “district courts have discretion to permit successive motions for summary judgment,” and that 2 doing so may “foster[] the ‘just, speedy, and inexpensive’ resolution of suits.” Hoffman v. 3 Tonnemacher, 593 F.3d 908, 911 (9th Cir. 2010) (quoting Fed. R. Civ. P. 1). Because of the 4 potential for abuse, courts retain discretion to “weed out frivolous or simply repetitive motions.” 5 Id. (quotation omitted). Additionally, district courts have broad authority to manage their dockets 6 and deny untimely motions absent good cause. Dietz v. Bouldin, 136 S.Ct. 1885, 1891–93 (2016); 7 Zivkovic v. Southern California Edison Co., 302 F.3d 1080, 1086 (9th Cir. 2002). 8 Novartis urges that a second summary judgment motion is warranted here, in light of 9 Idenix, because “all of the asserted claims are invalid for lack of enablement . . . .” See Mot. at 1– 10 2. Having considered Novartis’s arguments, the Court finds that Novartis fails to show good 11 cause to file a second motion for summary judgment. First, Idenix does not represent a change in 12 law that justifies Novartis’s delay in bringing the motion. In Idenix, the Federal Circuit considered 13 whether claims reciting compounds having a certain chemical formula, in addition to functional 14 limitations requiring an “effective” dose “for the treatment of a hepatitis C virus infection,” were 15 enabled. 941 F.3d at 1153–56. The court found that the claims were not enabled because 16 excessive experimentation was required to determine which compounds of the recited formula 17 were “effective against HCV.” Id. at 1162. In so doing, the court expressly noted that “[o]ur 18 decision in Wyeth and Cordis Corp. v. Abbott Laboratories compels this conclusion.” Id. In 19 Wyeth, the court had similarly found that claims that recited both functional and structural 20 limitations were not enabled because a person of ordinary skill in the art would have to test “tens 21 of thousands of compounds” to determine if they met the functional limitations. 720 F.3d 1380, 22 1384–85 (Fed. Cir. 2013). 23 Novartis provides no explanation as to why it could not have brought its desired motion 24 previously under Wyeth. A cursory examination of both cases shows that Idenix applies the rule 25 established in Wyeth and addresses a “striking[ly]” similar set of facts. 941 F.3d at 1162. 26 Accordingly, Novartis fails to show that it acted diligently, and therefore that it has good cause to 27 file the second motion for summary judgment after the dispositive motion deadline. See Johnson 1 cause” standard for modifying a schedule “primarily considers the diligence of the party seeking 2 the amendment”). 3 Second, the decision in Idenix does not apply to the current facts. The court in Idenix 4 addressed the question of whether “practicing the full scope of the claims would have required 5 excessive experimentation.” 941 F.3d at 1156, 1163. The claims there were limited to the “set of 6 compounds that are effective for treatment of HCV.” Id. at 1155 (quoting the claim construction 7 order). Thus, because the specification did not describe which compounds were effective for 8 treatment of HCV, it failed to enable “the full scope of the claims.” Id. at 1163. Here, in its 9 opening brief, Novartis argues that the asserted claims are not enabled because the specification 10 does not specify the compounds that are effective at inhibiting kinase. But kinase inhibition is not 11 a limitation of the asserted claims. See Dkt. No. 345-2 (“Proposed MSJ”) at 2:22–5:24 (quoting 12 asserted claims). At most, only claims 11 and 12 of the ’640 Patent even recite functional 13 limitations—but those limitations describe “treating a subject suffering from melanoma, thyroid 14 cancer or colorectal cancer,” not inhibiting kinase. See id. Thus, the specifications need not 15 enable compounds that inhibit kinase to allow a person of ordinary skill in the art to practice “the 16 full scope of the claims,” and Novartis’s motion will not resolve the dispute.1 See Idenix, 941 F.3d 17 at 1156. 18 Novartis changes tack in its reply, suggesting that its motion is also proper under the utility 19 standard of 35 U.S.C § 101, as utility is incorporated into the enablement analysis. See Dkt. No. 20 353 at 2, 5–6. Although Novartis is correct that utility has been incorporated into the enablement 21 standard, the two are not coextensive and require different types of analysis. See In re ’318 Patent 22 Infringement Litig., 583 F.3d 1317, 1323 (Fed. Cir. 2009) (noting enablement is “closely related” 23 to utility); Rasmusson v. SmithKline Beecham Corp., 413 F.3d 1318, 1323 (Fed. Cir. 2005) 24 1 Novartis argues in its reply that “every claim in the asserted patents is directed to compounds 25 that are useful as kinase inhibitors.” Dkt. No. 353 (“Reply”) at 6:10–11. However, “[i]t is a bedrock principle of patent law that ‘the claims of a patent define the invention to which the 26 patentee is entitled the right to exclude.’” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005) (en banc) (citation omitted). Since kinase inhibition is not required by the claims, it is not 27 required to practice the claimed invention. See CFMT, Inc. v. Yieldup Int’l Corp., 349 F.3d 1333, 1 (explaining how lack of usefulness leads to a rejection under both enablement and utility). 2 Utility requires a claimed invention to have “significant and presently available benefit to 3 || the public.” Grunenthal GMBH vy. Alkem Labs. Ltd., 919 F.3d 1333, 1345 (Fed. Cir. 2019) 4 || (quoting In re Fisher, 421 F.3d 1365, 1371 (Fed. Cir. 2005)). The bar for utility is “not high” and 5 only fails if the invention “is totally incapable of achieving a useful result.” Jd. (quoting 6 Brooktree Corp. v. Adv. Micro Devices, Inc., 977 F.2d 1555, 1571 (Fed. Cir. 1992)); see also id. 7 (explaining that “any pharmacological activity” satisfies utility). Ifa patent alleges a benefit, 8 || “[a]ll that is necessary is evidence that a POSA would accept the claimed utility as correct.” Id. at 9 1346. Enablement, by contrast, requires a patent specification to describe how to “make” and 10 “use” the invention without undue experimentation. In re Wands, 858 F.2d 731, 737 (Fed. Cir. 11 1988); 35 U.S.C. 112. “Ifa patent claim fails to meet the utility requirement because it is not 12 || useful or operative, then it also fails to meet the how-to-use aspect of the enablement 13 requirement.” Jn re ’318 Patent Infringement Litig., 583 F.3d at 1324. 14 Critically, however, /denix does not address utility or its relationship with enablement at 3 15 all. Novartis provides no explanation for why it could not have argued lack of utility in its first a 16 || motion for summary judgment, filed before the dispositive motion deadline. As both parties 3 17 acknowledge, this case is at a late stage, with pretrial filings submitted and trial set. Given these 18 circumstances, Novartis simply has not shown good cause to reopen dispositive motion briefing to 19 argue lack of enablement or lack of utility. 20 Accordingly, the Court DENIES Novartis’s motion for leave to file a second summary 21 || judgment motion. 22 IT IS SO ORDERED. 23 || Dated: 1/16/2020 24 Alapwrd & Mbt). HAYWOOD S. GILLIAM, JR. 25 United States District Judge 26 27 28